<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="204661">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000311</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-09413-1</org_study_id>
    <secondary_id>R01-09413-1</secondary_id>
    <nct_id>NCT00000311</nct_id>
  </id_info>
  <brief_title>Combining Behavioral Treatment With Agonist Maintenance - 1</brief_title>
  <official_title>Combining Behavioral Treatment With Agonist Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute on Drug Abuse (NIDA)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether the community reinforcement approach (CRA)
      plus contingency management (CM) is more effective overall than CRA only in reducing illicit
      opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up
      after completion of study protocol, and to compare the efficacy of maintenance on
      buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 1999</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Depression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal symptoms</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Opioid and cocaine use</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Social and psychological functioning</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>AIDS risk behavior</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment>168</enrollment>
  <condition>Cocaine-Related Disorders</condition>
  <condition>Opioid-Related Disorders</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Therapeutic Contracting (TC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cognitive Behavioral Coping Skills Therapy (CBT)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>Experimental Therapeutic Contracting (TC)
Experimental Cognitive Behavioral Coping Skills Therapy (CBT)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Please contact site for information.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Schottenfeld, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>APT Residential Services Division</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2008</verification_date>
  <lastchanged_date>October 27, 2008</lastchanged_date>
  <firstreceived_date>September 20, 1999</firstreceived_date>
  <responsible_party>
    <name_title>Richard S. Schottenfeld, MD</name_title>
    <organization>Yale University School of Medicine</organization>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
